期刊
DIABETES CARE
卷 33, 期 4, 页码 742-744出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc09-1600
关键词
-
资金
- National Institutes of Health [K23 DK068052]
- Takeda Pharmaceuticals, Lincolnshire, IL
- Takeda Pharmaceuticals North America
OBJECTIVE - To measure ghrelin and energy intake in the laboratory after pioglitazone treatment. RESEARCH DESIGN AND METHODS - This was a parallel, three-arm study with 51 obese diabetic subjects randomized to either 1) pioglitazone plus a portion-controlled diet (Pio + PC), 2) pioglitazone plus American Diabetes Association (ADA) dietary advice (Pio+ADA), or 3) metformin plus ADA advice (Met+ADA). Energy intake and the suppressive response of a meal on ghrelin were measured at weeks 0 and 16. Mixed models tested if changes from week 0 10 16 differed by group. RESULTS - The Pio+ADA group had a significantly larger increase (P < 0.05) in energy intake ((adjusted means +/- SE] 207 +/- 53 kcal) compared with the Pio + PC (50 +/- 46 kcal) and Met+ADA (52 +/- 49 kcal) groups. Change in restraint and disinhibition (variables associated with eating behavior) mediated weight change. Ghrelin suppression increased in the Pio + ADA group, which gained weight. CONCLUSIONS - A portion-controlled diet attenuated the increase in energy intake after pioglitazone. Ghrelin responded to weight change not pioglitazone exposure.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据